Fermenta Biotech FY26 Annual Report: Revenue hits record Rs 548 crore

Revenue Growth 20pctEbitda Margin ExpansionExceptional ItemResults View source PDF Explain this filing

FERMENTA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.3%Reaction day

₹442.85

prior close

₹447.30

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.3%-2.6% vs market

Pharmaceuticals peers, median of 165sector+0.1%-2.4% vs sector

On the reaction day the stock moved 2.6 pts less than Nifty Microcap 250 and 2.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.0

10m

-2.5

15m

-2.3

30m

-2.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.3+0.3-2.6+0.1-2.4

Next day

-5.1-0.9-4.2-1.5-3.6

-10.0-1.5-8.4-2.1-7.9

-2.4-1.1-1.3-2.2-0.2

-0.7+0.2-0.9-1.6+0.8

+3.9-1.1+4.9-2.4+6.3

+4.8-1.2+6.0-2.6+7.4

15d

+7.8+3.1+4.6+0.1+7.7

+8.0+4.5+3.5-0.7+8.7

+7.0+4.5+2.5+0.9+6.1

+6.1-2.2+8.4-6.0+12.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Fermenta Biotech filed its FY26 Annual Report ahead of the August 11 AGM. Consolidated revenue rose 14% to a record Rs 548 crore; excluding real estate, core revenue grew 26%. Core EBITDA jumped 44% to Rs 120 crore. Reported PAT was Rs 70 crore versus Rs 76 crore in FY25, with underlying PAT stronger after stripping real-estate one-offs. Operating cash flow more than doubled to Rs 93 crore and free cash flow tripled to Rs 62 crore. Debt-to-equity eased to 0.27.

Likely market impact

Record topline and doubled cash flow signal operating momentum. New patent and Rs 110 crore capex position company for plant-source Vitamin D3 leadership.